{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:20:00Z","timestamp":1739942400623,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1124\/dmd.118.082081","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T18:45:40Z","timestamp":1535654740000},"page":"1478-1486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gene-by-Environment Interaction of Bcrp\u2212\/\u2212 and Methionine- and Choline-Deficient Diet\u2013Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition"],"prefix":"10.1016","volume":"46","author":[{"given":"Erica L.","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika L.","family":"Dzierlenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vildhede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Goedken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.082081_bib1","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","author":"Ali","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082081_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/pds.1984","article-title":"Adverse drug events in the outpatient setting: an 11-year national analysis","volume":"19","author":"Bourgeois","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/dmd.118.082081_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(24)36601-7","article-title":"Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats","volume":"281","author":"Chu","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.082081_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.118.082081_bib6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"key":"10.1124\/dmd.118.082081_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jchromb.2008.10.011","article-title":"A liquid chromatography\/electrospray ionization mass spectrometry (LC-MS\/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples","volume":"875","author":"D\u2019Esposito","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.082081_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.114.220764","article-title":"Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis","volume":"352","author":"Dzierlenga","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.082081_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/jpet.116.234310","article-title":"Biliary elimination of pemetrexed is dependent on Mrp2 in rats: potential mechanism of variable response in nonalcoholic steatohepatitis","volume":"358","author":"Dzierlenga","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.082081_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/fcp.12117","article-title":"UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice","volume":"29","author":"Etienne-Grimaldi","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.118.082081_bib11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.118.082081_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082081_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.118.082081_bib14","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.115.066712","article-title":"Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of CPT-11","volume":"44","author":"Fujita","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/toxsci\/kfu156","article-title":"Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis","volume":"142","author":"Hardwick","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.118.082081_bib16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib17","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1196\/annals.1377.020","article-title":"Pharmacogenetic approach for cancer treatment-tailored medicine in practice","volume":"1086","author":"Hasegawa","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/dmd.118.082081_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3892\/ol.2011.533","article-title":"Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene","volume":"3","author":"Hirose","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1124\/dmd.118.082081_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1023\/A:1020358910490","article-title":"Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats","volume":"19","author":"Horikawa","year":"2002","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.082081_bib22","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.118.082081_bib23","unstructured":"Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611\u2013616."},{"key":"10.1124\/dmd.118.082081_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1535-7163.MCT-13-0541","article-title":"OATP1A\/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice","volume":"13","author":"Iusuf","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.118.082081_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","article-title":"UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity","volume":"2","author":"Iyer","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.118.082081_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.118.082081_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0300-483X(02)00458-4","article-title":"Toxicological implications of hepatobiliary transporters","volume":"181\u2013182","author":"Kato","year":"2002","journal-title":"Toxicology"},{"key":"10.1124\/dmd.118.082081_bib28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1006\/bbrc.2001.4267","article-title":"Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells","volume":"280","author":"Kawabata","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.118.082081_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpba.2004.09.053","article-title":"A simple and sensitive LC\/MS\/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38)","volume":"37","author":"Khan","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.118.082081_bib30","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.118.082081_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/clpt.2012.79","article-title":"A perspective on efflux transport proteins in the liver","volume":"92","author":"K\u00f6ck","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082081_bib33","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2006.07.2355","article-title":"Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity","volume":"24","author":"Kroetz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.118.082081_bib34","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/dmd.111.040592","article-title":"Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease","volume":"39","author":"Lake","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082081_bib35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","article-title":"Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1124\/dmd.118.082081_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.118.082081_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","article-title":"Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis","volume":"14","author":"Marra","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1124\/dmd.118.082081_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2133\/dmpk.DMPK-12-RG-026","article-title":"Impact of genetic variation in breast cancer resistance protein (BCRP\/ABCG2) on sunitinib pharmacokinetics","volume":"27","author":"Mizuno","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.082081_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2008.07.003","article-title":"Functions of the breast cancer resistance protein (BCRP\/ABCG2) in chemotherapy","volume":"61","author":"Noguchi","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.118.082081_bib41","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1093\/hmg\/ddi261","article-title":"Pharmacogenetics\/genomics and personalized medicine","volume":"14 Spec No. 2","author":"Sad\u00e9e","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1124\/dmd.118.082081_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3322\/caac.21220","article-title":"Colorectal cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/dmd.118.082081_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clpt.2004.03.003","article-title":"Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype","volume":"76","author":"Sparreboom","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082081_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1472-6963-14-125","article-title":"International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA","volume":"14","author":"Stausberg","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1124\/dmd.118.082081_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semcdb.2014.12.001","article-title":"N-linked sugar-regulated protein folding and quality control in the ER","volume":"41","author":"Tannous","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"10.1124\/dmd.118.082081_bib46","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3892\/ol.2016.4937","article-title":"ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan","volume":"12","author":"Tuy","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1124\/dmd.118.082081_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1042\/bss0720039","article-title":"N-glycans as apical targeting signals in polarized epithelial cells","volume":"72","author":"Urquhart","year":"2005","journal-title":"Biochem Soc Symp"},{"key":"10.1124\/dmd.118.082081_bib48","doi-asserted-by":"crossref","unstructured":"Wang X, Rao Z, Qin H, Zhang G, Ma Y, Jin Y, Han M, Shi A, Wang Y, Wu X (2016) Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats. Biopharm Drug Dispos 37:421\u2013432.","DOI":"10.1002\/bdd.2024"},{"key":"10.1124\/dmd.118.082081_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the International Transporter Consortium","author":"Yee","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082081_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1124\/dmd.118.082081_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.082081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:37:43Z","timestamp":1739903863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624056034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0090955624056034"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.082081","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene-by-Environment Interaction of Bcrp\u2212\/\u2212 and Methionine- and Choline-Deficient Diet\u2013Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.082081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}